Xin Lang Cai Jing·2026-02-11 05:29Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - As of September 30, 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a significant increase of 213.21% [2] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] Group 2 - As of February 10, 2023, the company's financing balance reached 50 million yuan, accounting for 0.75% of its market capitalization, indicating a high level of financing activity [1] - The company had a net financing purchase of 1.46 million yuan on February 10, 2023, with a total financing buy of 4.19 million yuan and repayment of 2.73 million yuan [1] - The company’s stock has seen an increase in shareholder accounts, with a total of 6,164 shareholders as of September 30, 2025, reflecting a 4.12% increase [2]